About Seladelpar API
Therapeutic CategoryHepatology
CAS Number
851528‑79‑5
API Technology
Small‑molecule synthetic API
Dose Form
Oral Solid/Capsules
Dr Reddy's Development Status
Under Development
Mechanism of action
Seladelpar activates PPAR‑δ, a nuclear receptor expressed in the liver and other tissues.
PPAR‑δ activation:
Reduces bile acid synthesis via FGF21‑mediated downregulation of CYP7A1, the rate‑limiting enzyme in bile acid production
Decreases cholesterol synthesis and absorption
Lowers hepatic and circulating bile acid levels
These effects result in:
Reduced cholestatic liver injury
Improvement in biochemical markers (e.g., alkaline phosphatase)
Reduction in pruritus, partly associated with decreased interleukin‑31 levels
Indication
Approved indication (FDA / EMA):
Treatment of primary biliary cholangitis (PBC) in adults:
In combination with ursodeoxycholic acid (UDCA) in patients with inadequate response to UDCA, or
As monotherapy in patients unable to tolerate UDCA
Related APIs
Seladelpar
Hepatology
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Disclaimer
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.